Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon Alfa-2a in Chronic Hepatitis B Patients With Cirrhosis
NCT03084250Phase 4Unknown
- Sponsor
- Shanghai Pudong New Area Nanhua Hospital
- Start
- Mar 2017
- Primary completion
- Apr 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a in hepatitis B (HBV) (2 arms), sponsored by Shanghai Pudong New Area Nanhua Hospital. Primary endpoint: Number of subjects who develop to hepatocellular carcinoma at 5 years. Status: unknown.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT03084250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03084250.